Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

NASDAQ:BFRI

Biofrontera Inc.

Last Close

1.26

25/09 14:39

Market Cap

4.99M

Beta: -

Volume Today

153.83K

Avg: 99.87K

PE Ratio

−0.05

PFCF: −0.07

Filings Not Available